Eli Lilly And Company ((LLY)), Pfizer Inc ((PFE)), ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer, in collaboration with Eli Lilly and Company, ONO Pharmaceutical Co., and Merck KGaA, is conducting a Phase 3 clinical study titled ‘AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER.’ The study aims to evaluate the efficacy of encorafenib plus cetuximab, with or without chemotherapy, compared to standard chemotherapy in patients with metastatic colorectal cancer with the BRAF V600E mutation. This study is significant as it explores new treatment combinations for a cancer type that has spread and has not been previously treated.
The study tests two main interventions: encorafenib plus cetuximab, and the same combination with additional chemotherapy. Encorafenib and cetuximab are administered orally and intravenously, respectively, aiming to improve treatment outcomes for patients with specific genetic mutations in their cancer.
This interventional study is randomized and follows a parallel assignment model, with no masking involved. The primary purpose is treatment, focusing on assessing the effectiveness of the new drug combinations against the standard care.
The study began on December 21, 2020, and is currently active but not recruiting new participants. The last update was submitted on August 12, 2025. These dates are crucial as they mark the progress and current status of the study, indicating that results are still being gathered and analyzed.
The outcome of this study could significantly impact the market, particularly for Pfizer, Eli Lilly, and ONO Pharmaceutical, as successful results might boost their stock performance and investor confidence. The study’s findings could also influence the competitive landscape in the oncology sector, potentially setting new standards for treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.